Genentech withdraws psoriasis drug Raptiva in US over PML risk
This article was originally published in Scrip
Executive Summary
Genentech is to withdraw its psoriasis therapy Raptiva (efalizumab) in the US based on its association with an increased risk of developing progressive multifocal leucoencephalopathy (PML), a rare and potentially fatal brain infection.